Renovo is well funded and its future strategy is aimed at maximising shareholder value. The Company has become an investing company and will consider all options available to it in addition to realising value, where possible, from its remaining portfolio of clinical and preclinical candidates and intellectual property. The directors do not intend to place any restrictions on the nature of the business carried out by potential acquisition and merger targets. Renovo’s cost base is being minimised wherever possible in order to maximise the Company’s available cash. The Investing Policy adopted by members in General Meeting on 24 January 2013 is available here.